Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal (vol 36, pg 39, 2018)

被引：0
|
作者：
Tikhonova, Irina A. [1 ]
Jones-Hughes, Tracey [1 ]
Dunham, James [1 ]
Warren, Fiona C. [1 ]
Robinson, Sophie [1 ]
Stephens, Peter [2 ]
Hoyle, Martin [1 ]
机构：
[1] Peninsula Technol Assessment Grp PenTAG, Exeter, Devon, England
[2] Royal Devon & Exeter NHS Fdn Trust, Exeter, Devon, England
来源：
PHARMACOECONOMICS | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1007/s40273-018-0635-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
Page 41, Column 1, Section 3.1, paragraph 2, 1st sentence which.
引用
收藏
页码：507 / 507
页数：1
相关论文
共 7 条
  • [1] Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal
    Irina A. Tikhonova
    Tracey Jones-Hughes
    James Dunham
    Fiona C. Warren
    Sophie Robinson
    Peter Stephens
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 507 - 507
  • [2] Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
    Tikhonova, Irina A.
    Jones-Hughes, Tracey
    Dunham, James
    Warren, Fiona C.
    Robinson, Sophie
    Stephens, Peter
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (01) : 39 - 49
  • [3] Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
    Irina A. Tikhonova
    Tracey Jones-Hughes
    James Dunham
    Fiona C. Warren
    Sophie Robinson
    Peter Stephens
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 39 - 49
  • [4] Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (vol 36, pg 399, 2018)
    Mistry, Hema
    Nduka, Chidozie
    Connock, Martin
    Colquitt, Jill
    Mantopoulos, Theodoros
    Loveman, Emma
    Walewska, Renata
    Mason, James
    PHARMACOECONOMICS, 2019, 37 (06) : 869 - 869
  • [5] Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
    Irina A. Tikhonova
    Martin W. Hoyle
    Tristan M. Snowsill
    Chris Cooper
    Joanna L. Varley-Campbell
    Claudius E. Rudin
    Ruben E. Mujica Mota
    PharmacoEconomics, 2017, 35 : 363 - 373
  • [6] Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
    Tikhonova, Irina A.
    Hoyle, Martin W.
    Snowsill, Tristan M.
    Cooper, Chris
    Varley-Campbell, Joanna L.
    Rudin, Claudius E.
    Mota, Ruben E. Mujica
    PHARMACOECONOMICS, 2017, 35 (03) : 363 - 373
  • [7] DEMONSTRATING CLINICAL-EFFECTIVENESS USING INDIRECT AND MIXED TREATMENT COMPARISON ANALYSIS: A REVIEW OF MANUFACTURERS' SINGLE TECHNOLOGY APPRAISAL (STA) SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)
    Bending, M. W.
    Hutton, J.
    McGrath, C.
    VALUE IN HEALTH, 2011, 14 (03) : A21 - A21
1